These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38193121)

  • 1. PEGylated therapeutics in the clinic.
    Gao Y; Joshi M; Zhao Z; Mitragotri S
    Bioeng Transl Med; 2024 Jan; 9(1):e10600. PubMed ID: 38193121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
    Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
    J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induction of Anti-PEG Immune Responses by PEGylation of Proteins].
    Shimizu T; Ishima Y; Ishida T
    Yakugaku Zasshi; 2020; 140(2):163-169. PubMed ID: 32009039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of PEGylation on biological therapies.
    Veronese FM; Mero A
    BioDrugs; 2008; 22(5):315-29. PubMed ID: 18778113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.
    Zhang X; Wang H; Ma Z; Wu B
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1691-702. PubMed ID: 25270687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging PEGylated non-biologic drugs.
    Park EJ; Choi J; Lee KC; Na DH
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):107-119. PubMed ID: 30957581
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies.
    Freire Haddad H; Burke JA; Scott EA; Ameer GA
    Regen Eng Transl Med; 2022; 8(1):32-42. PubMed ID: 33786367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery.
    Milla P; Dosio F; Cattel L
    Curr Drug Metab; 2012 Jan; 13(1):105-19. PubMed ID: 21892917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies against polyethylene glycol in human blood: A literature review.
    Hong L; Wang Z; Wei X; Shi J; Li C
    J Pharmacol Toxicol Methods; 2020; 102():106678. PubMed ID: 31981619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGYLATION: an important approach for novel drug delivery system.
    Yadav D; Dewangan HK
    J Biomater Sci Polym Ed; 2021 Feb; 32(2):266-280. PubMed ID: 32942961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications.
    Banerjee SS; Aher N; Patil R; Khandare J
    J Drug Deliv; 2012; 2012():103973. PubMed ID: 22645686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEG - a versatile conjugating ligand for drugs and drug delivery systems.
    Kolate A; Baradia D; Patil S; Vhora I; Kore G; Misra A
    J Control Release; 2014 Oct; 192():67-81. PubMed ID: 24997275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.
    Zhang P; Sun F; Liu S; Jiang S
    J Control Release; 2016 Dec; 244(Pt B):184-193. PubMed ID: 27369864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylation: a novel process for modifying pharmacokinetics.
    Harris JM; Martin NE; Modi M
    Clin Pharmacokinet; 2001; 40(7):539-51. PubMed ID: 11510630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin inhalation--Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin--Nektar, PEGylated insulin--Nektar.
    Drugs R D; 2004; 5(3):166-70. PubMed ID: 15139780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylation and its impact on the design of new protein-based medicines.
    Ginn C; Khalili H; Lever R; Brocchini S
    Future Med Chem; 2014; 6(16):1829-46. PubMed ID: 25407370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging PEGylated drugs.
    Kang JS; Deluca PP; Lee KC
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):363-80. PubMed ID: 19453284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in PEGylation of important biotech molecules: delivery aspects.
    Ryan SM; Mantovani G; Wang X; Haddleton DM; Brayden DJ
    Expert Opin Drug Deliv; 2008 Apr; 5(4):371-83. PubMed ID: 18426380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylation: engineering improved biopharmaceuticals for oncology.
    Molineux G
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):3S-8S. PubMed ID: 12921216
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.